CA2098033A1 - Process for preparing cyclobutane purines - Google Patents

Process for preparing cyclobutane purines

Info

Publication number
CA2098033A1
CA2098033A1 CA002098033A CA2098033A CA2098033A1 CA 2098033 A1 CA2098033 A1 CA 2098033A1 CA 002098033 A CA002098033 A CA 002098033A CA 2098033 A CA2098033 A CA 2098033A CA 2098033 A1 CA2098033 A1 CA 2098033A1
Authority
CA
Canada
Prior art keywords
carbons
group
formula
iodo
branched chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002098033A
Other languages
French (fr)
Inventor
Janak Singh
Gregory S. Bisacchi
Jollie D. Godfrey
Toomas Mitt
Richard H. Mueller
Robert Zahler
Thomas P. Kissick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2098033A1 publication Critical patent/CA2098033A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/40Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

ABSTRACT Process For Preparing Guanine-Containing Antiviral Agents And Purinyl Salts Useful In Such Process A purine salt of the formula wherein Y1 is chloro, bromo, or iodo, and R1, R2, R3, and R4 are independently selected from alkyl and substituted alkyl is reacted with the compound of the formula Z1-X to yield the purine of the formula wherein X is a leaving group, and Z1 is a protected form of the carbohydrate surrogate Z. Several routes are disclosed for converting this intermediate to the antiviral agent

Description

20980~3 Process Fo~ preparina Gu~nine-~Qn~ainina Antiviral Aaents A~_Pu~in~l Salts Usç~u~ uch P~oçess Antiviral agents having a guaninyl substituent on a carbohydrate surrogate are known. Eor example, the compound [lR-( 1~,2~, 3a) ] -2-amino-9-[2,3-bis(hydroxymethyl)cyclobutyl]-1,9-dihydro-6H-purin-6-one, i.e., I~N~ ' HOHz~

is an antiviral agent with activity against herpes simplex virus type 1 and 2, varicella zoster virus, human cytomeglavirus, vaccina virus, murine leukemia virus, and human immunodeficiency virus. Methods for the preparation of this antiviral agent are disclosed in U. S. Patents 5,064,961 and 5,153,352 and European Patent Application 358,154.
The tetrabutylammonium salt of 2-amino-6-benzyloxypurine is disclosed in European Patent Applications 55,239 and 458,363.

209~3
- 2 - GY26a This invention is directed to a process for preparing antiviral compounds of the formula (I) N ~ N~ .

N N
z wherein z is a carbohydrate surrogate by reacting a purine salt of the formula (II) ~ < ~ ~ 1 ) j Rl - N -with the compound of the formula (III) Zl--X

2098~33 _ 3 _ GY26a to yield the purine of the formula (IV) Y

<NXN~) NH~

wherein x is a leaving group, Z1 is a protected form of carbohydrate surrogate z, Y1 is iodo, bromo, or chloro, and R1, R2, R3, and R4 are independently straight or branched chain alkyl of 1 to 10 carbons or substituted straight or branched chain alkyl of 1 to 10 carbons. The compound of formula IV is then converted to the antiviral agent of formula I.
In the preferred process of this invention, the antiviral agent of formula I is [lR-(la,2~,3a)]-2-amino-9-~2,3-bis(hydroxymethyl)cyclobutyl]-1,9-dihydro-6H-purin-6-one and it is prepared by reacting a purine salt of formula II with the bis(2,3-protected hydroxymethyl) cyclobutane of the formula (V) Prot-o-H2~ x CH2-O-Prot wherein Prot is a hydroxy protecting group. This reaction yields the cyclobutyl purine of the formula ~V9~13~
_ 4 _ GY26a (VI) Y

<N~

Prot-O-H2C ~

CH2-O-Prot which is then converted to the antiviral agent [lR-(la, 2~,3a)~-2-amino-9-[2,3-bis(hydroxymethyl)-cyclobutyl]-l,9-dihydro-6H-purin-6-one.
The bis(2,3-protected hydroxymethyl)-cyclobutane of formula V is optically active, the relative sterochemistry of the substituent x is drawn to indicate that the leaving group X is cis to the vicinal -CH2-0-Prot substituent and that the two -CH2-0-Prot substituents are trans to each other.
This invention is also directed to the novel purine salts of formula I.

209~033 GY26a The term ~alkyl~ refers to straight and branched chain groups of 1 to 10 carbons. The term ~substituted alkyl a refers to such alkyl groups of 1 to 10 carbons having one, two or three substituents, preferably one, selected from alkoxy of 1 to 6 carbons and aryl. The term ~aryl~ refers to phenyl and phenyl having one, two, or three substituents, preferably one, selected from alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, chloro, bromo, iodo, and fluoro.
The carbohydrate surrogate Z includes cyclized and acyclic moieties which possess antiviral activity when substituted with a guanine moiety. Suitable groups for Z include F

HOH2C--OI HOH2C~

HOH2C_~y OH

HOH2C _ ~ HOH2C _ ~

209~3 - 6 - GY26a HOH2C_~ HOH2C_~

OH OH

HOH2C--~ HOH2C ~

o ~ ~ HO-p~o ~ ~ and O CH2oH
HO-P ~ O
OH

Z1 represents the moiety Z wherein the hydroxy groups are protected. Suitable hydroxy protecting groups include hindered silyl groups such as t-butyl-dimethylsilyl, t-butyldiphenylsilyl, (triphenyl-methyl)dimethylsilyl, methyldiisopropylsilyl and triisopropylsilyl, benzyl and substituted benzyl groups such as p-methoxybenzyl, acyl groups of the Il formula C - Rs wherein Rs is a straight or branched chain lower alkyl of 1 to 6 carbons, or phenyl, especially acetyl or benzoyl, trityl, and substituted trityl groups such as 4-monomethoxy trityl or 4,4'-dimethoxytrityl.

GY26a x in the compounds of formula III is a leaving group such as chloro, bromo, iodo, an aryl sulfonyloxy group such as p-toluenesulfonyloxy, an alkyl sulfonyloxy group such as methanesulfonyloxy, a substituted alkyl sulfonyloxy group, preferably a perfluoroalkanesulfonyloxy group such as trifluoromethanesulfonyloxy, a nitro-substituted benzene sulfonyloxy group such as p-nitro-benzenesulfonyloxy, or fluorosulfonyloxy.
The compounds of formula III are prepared according to known procedures or as set forth below.
For example, the bis(2,3-protected hydroxymethyl)-cyclobutane of formula V can be prepared as taught by Bisacchi et al. in U.S. Patent 5,064,961. For example, when X is a perfluoroalkane sulfonyloxy group such as trifluoromethanesulfonyloxy, the perfluoroalkanesulfonic anhydride such as trifluoromethanesulfonic anhydride is reacted with the diprotected 2,3- hydroxymethyl cyclobutanol of the formula (VII) Prot-O-H2C ~ ~ OH

CH2-O-Prot in an inert solvent such as methylene chloride or chloroform, preferably methylene chloride, in the presence of a base such as pyridine or triethylamine, preferably pyridine. The reaction can be run at from about -20C. to the boiling point of the solvent, preferably at about 0C. to room temperature.

;.

2 ~ 3 3 GY26a When X is a nitro-substituted benzene sulfonyloxy group such as p-nitrobenzenesulfonyloxy, the cyclobutanol of formula VII is reacted with a nitro-substituted benzene sulfonating reagent such as p-nitrobenzenesulfonyl chloride in pyridine or in an inert solvent such as methylene chloride or chloroform containing a base such as pyridine or triethylamine.
When X is fluorosulfonyloxy, the cyclobutanol of formula VII is reacted with fluorosulfonic anhydride in pyridine or in an inert solvent such as methylene chloride or chloroform containing a base such as pyridine or triethylamine.
The compounds of formula III

Prot-O-H2c~ x --Prot-O

can be prepared from the pyran of the formulas (VIII) Prot-O-H2C ~ lullllOH

Prot-O

or , .

209~V33 GY26a g (IX) Prot-O-H2C ~ OH

Prot-O

For example, treatment of the compound of formula VIII with p-toluenesulfonyl chloride in pyridine, or methanesulfonyl chloride and triethylamine, or trifluoromethanesulfonic anhydride and pyridine affords the corresponding compounds of formula III
wherein x is ~-toluenesulfonyloxy, methane-sulfonyloxy, or trifluoromethanesulfonyloxy,respectively.
Alternatively, these compounds of formula III
wherein X is ~-toluenesulfonyloxy can also be prepared from the isomerlc compound of formula IX by known methods ~see I. Galynker et al., Tetrahedron Letters, 23, 4461(1982)]. For example, treatment of compound IX with diethyl or diisopropyl azodi-carboxylate in the presence of triphenylphosine, and zinc ~-toluenesulfonate affords the compound of formula III wherein X is ~-toluenesulfonyloxy.
Alternatively, these compounds of formula III wherein x is p-toluenesulfonyloxy or methanesulfonyloxy can also be prepared from the compound of formula IX by treatment with ~-toluenesulfonic acid or methane-sulfonic acid, respectively, in the presence oftriethylamine, triphenylphosine, and diethyl or diisopropyl azodicarboxylate in a solvent such as toluene, ether, or dioxane.
These compounds of formula III wherein x is chloro, bromo, or iodo can be prepared by treatin~ a compound of formula IX with a methyltriphenoxy-GY26a phosphonium halide or methyltriphenylphosphonium halide (i.e., chloride, bromide, or iodide) in a solvent such as dimethylformamide. Alternatively, these compounds of formula III wherein x i5 chloro, bromo, or iodo can be prepared from the compound of formula IX using triphenylphosphine, diethyl or diisopropyl azodicarboxylate, and a source of halide such as methyl iodide, methyl bromide, or methylene chloride according to methodology known in the art.
See, for example, H. Loibner et al., Helv. Chim.
Acta., S9, 2100 (1976).
The compounds of formulas VIII and IX can be prepared from the known compound of formula X [See M.
Okabe et al., Tetrahedron Letters, 30, 2203 (1989);
M. Kugelman et al., J. Chem. Soc. Perkin I, 1113(1976); B. Fraser-Reid et al., J. Amer. Chem.
Soc., ~, 6661(1970) for the preparation of the compound of formula X~ as outlined below:
HO-H2C~3 Prot -O-H2C~3 HO Prot-O
(x) (XI) VIII + IX
Treatment of the compound of formula X with various hydroxyl protecting reagents known in the art affords the compounds of formula XI.
The compound of formula XI wherein the hydroxy protecting groups are acetyl can also be obtained by the direct reduction of tri-O-acetyl-D-glucal, i.e.

.
.

2098~)3 GY26a H3C-C-O-H2C--~ ~

H3C-C-O` ~

see N. Greenspoon et al., J, Org. Chem., 53, 3723 (1988). Alternatively, this compound of formula XI
can also be obtained by treatment of tri-O-acetyl-D-glucal with sodium borohydride in the presence of Cu(I)Br and tetrakis(triphenylphosphine)-palladium(o~ in an aprotic solvent such as tetrahydrofuran and/or dimethoxyethane.
Hydroboration of the compound of formula XI
with borane-tetrahydrofuran complex followed by treatment with aqueous sodium bicarbonate and 30%
hydrogen peroxide affords a mixture of the compound of formula VIII and the isomeric compound of formula IX which can be separated, e.g., by chromatography on silica gel.
The compounds of formula III
F

Prot-O-H2C ~ X

CH2-O-Prot are taught by Zahler et al. in European Patent Application 458,363.
The compounds of formula III

209~033 GY26a Prot-O-H~C ~ n~ x are taught by Slusarchyk in European Application 352,013.
5The compounds of formula III
O~
Prot-O-H2C ~ ~ X

CH2-O-Prot are taught by Zahler et al. in U.S. Patent 5,059,690.
10The compounds of formula III

Prot-O-H2C ~ ul~ x Prot-O

are taught by Ravenscroft in U.S. Patent 4,658,044.
15The compounds of formula III

Prot-O-H2C~~~ lX Prot-O-H2C_~IIlllllX

Prot-O Prot-O

are taught by Borthwick et al., ~. Chem. Soc. Chem.
Commun., 1988, p. 656-658.

' 21D~Q33 GY26a The compounds of formula III

Prot-O-H2C ~ ..~lln-lX
Prot -0/

Prot-0 are taught by Hanna et al., J. Heterocyclic Chem., Vol. 25, p. 1899 - 1903 (1988).
Slmilarly, the acyclic compounds of formula III are taught in the literature as note Martin et al., Nucleosides ~ Nucleotides, Vol. 8, p. 923-926 (1989); Bronson et al., J. Med. Chem., Vol. 32., p. 1457-1463 (1989); Harden et al., J. Med. Chem., Vol. 30, p 1636-1642 (1987) and J. Med. Chem., Vol.
32, p. 1738-1743 (1989); and Kim et al., J. Med.
Chem., Vol. 33, p. 1207-1213 (1990) and J. Med.
Chem., Vol. 33, p. 1797-1800 (1990).
The purine salts of formula II are prepared by reaction of a purine compound of the formula (XII) Yl N~N J--NH2 Z
with a compound of the formula 2 ~ 3 3 GY2~a (XIII) ( Rl I - R4 ) OH

in a solvent such as ethanol or methylene chloride and water followed by isolation of the salt from the reaction.
The purine compound of formula XII wherein Yl is chloro is commercially available or can be prepared by known methods. The purine of formula XII wherein Yl is bromo can be prepared by the procedure described by R.K. Robins et al., J. Org. Chem., 27, 98 (1962). The compound of formula XII wherein Yl is iodo can be prepared by treatment of the compound of formula XII wherein Yl is chloro with aqueous hydroiodic acid at about 1C.
The compounds of formula XIII are known in the art and are either commercially available or can be prepared by published methods.
The reaction between the purine salt of formula II and the compound of formula III is run in an aprotic solvent such as methylene chloride, acetonitrile, acetone, tetrahydrofuran, and the like at a temperature of from about -20 to 100C. for from about 30 minutes to about 24 hours, preferably from about one hour to about 12 hours. When X is a perfluoroalkanesulfonyloxy group such as trifluoro-methylsulfonyloxy, the solvent employed is pre-ferably methylene chloride and the reaction is run at from about 0C. to about 30C. When X is a nitro-substltuted benzenesulfonyloxy group such as p-, - 15 - GY2 6a nitrobenzenesulfonyloxy, the solvent employed is preferably acetonitrile and the reaction is run at from about 30C. to about 90C.
The resulting intermediate of formula IV is converted to the desired antiviral agent of formula I
by selective removal of the hydroxy protecting group or groups in Zl and conversion of the Yl group to a 6-oxo. For example, when the hydroxy protecting group or groups in the compound of formula IV are acyl treatment with catalytic sodium methoxide in methanol yields the compound of the formula (XIV) Y

Similarly, when the hydroxy protecting group or groups in the compound of formula IV are hindered silyl groups treatment with fluoride ion such as tetrabutylammonium fluoride yields the compound of formula XIV and when the hydroxy protecting group or groups in the compound of formula IV are benzyl or substituted benzyl treatment with boron trichloride yields the compound of formula XIV. Acid hydrolysis of the compound of formula XIV such as by using hot aqueous hydrochloric acid gives the desired 6-oxo antiviral agent of formula I.
Alternatively, treatment of the compound of formula IV wherein the hydroxy protecting group or groups are acyl, benzyl, or substituted benzyl with hot aqueous acid effects selective conversion of the .

GY26a Y1 group to a 6-oxo group to provide a compound of the formula (xv) U

N N
I

Zl wherein the hydroxy group or groups in Z1 are protected by an acyl, benzyl, or substituted benzyl.
In this reaction, when the protecting group or groups are acyl and Y1 is iodo treatment of the compound of formula IV with hot aqueous acetic acid yields the compound of formula XV. when the hydroxy protecting group or groups are benzyl or substituted benzyl and Y1 is chloro, bromo or iodo treatment of the compound of formula IV with hot aqueous hydrochloric acid yields the compound of formula XV. The hydroxy protecting group or groups can then be removed fro~
the compound of formula XV by the methods described above or other known methods in the art to give the desired antiviral agents of formula I. For example, when the hydroxy protecting group or groups are an acyl such as benzoyl treatment with aqueous sodium hydroxide or sodium methoxide in methanol will give the desired final product. Similarly, when the hydroxy protecting group or groups is benzyl or substituted benzyl hydrogenolysis will give the desired product.
In a further alternate procedure, the compound of formula XIV or the hydroxy protected compound of formula IV wherein the protecting group or groups are acyl can be treated with excess sodium methoxide in - '. : . , GY2 6a methanol at reflux to provide a compound of the formula (XVI) <~3~NJ--N~12 Acid hydrolysis, for example, using hot aqueous hydrochloric acid, of the compound of formula XVI
gives the desired 6-oxo antiviral agent of formula I.
AlternatiYely, treatment of a compound of formula IV wherein the hydroxy protecting group or groups are acyl with hot aqueous hydroxide such as sodium or potassium hydroxide or with an acid such as hydrochloric acid followed by sodium or potassium hydroxide and heating gives the desired 6-oxo antiviral agent of formula I.
Preferably, the process of this invention employs the compounds of formula III wherein Zl--X is ~rot-o-X~C~ o-lX

CH2-O-Prot 2~98033 GY26a F

Prot-O-H2C ~ ~ X
=

CH2-O-Prot O~
Prot-O-H2C _~)IIIIIIX

CH2-O-Prot O~
Prot-O-H2C ~ l~lllllllx _ , or -5Prot-O

Prot-O-~ ~C~ X

CH2-O-Prot Prot is acetyl or benzoyl.
10 X is p-nitrobenzenesulfonyloxy or trifluoromethanesulfonyloxy.
Preferred purine salts of formula I for use within the process of this invention are those wherein:
15 Y1 is chloro or iodo, especially iodo.
R1, R2, R3 and R4 are each n-butyl or R1, R2, and R3 are ethyl and R4 is benzyl.

GY26a This preferred process, particularly when ~1--X iS

~C--O --H2C _OIIIIInO-SO2-CF3 CH2 -O-C--@

can be performed under milder reaction conditions, in a shorter period of time, and with higher yields than previously reported process for preparing the antiviral agents of formula I.
The following examples are illustrative of the invention.

2~9~13~
GY26a Example 1 ~lR- (la.2~ 3a)l-2-Amino-9-~2,~-bis(hvdrox~Ymethyl)-cyclobuty~-,L,9-dihydro-6H-Durin-~-Qn~
a) 6-Iodo-9H-~uri~-?-amine 6-Chloro-9H-purin-2-amine (5.0 g., 29.5 mmole) was added to 47% hydrogen iodide (61 ml., 12.2 ml./g.) chilled in an ice bath. After 1.5 hours, water (61 ml.) was added and the mixture stirred in an ice- bath for 30 minutes. The yellow solid was filtered out and the filter cake was washed with water. The wet solid was transferred to a beaker and the residue in the funnel was washed into the beaker with water (30 ml.). 6M Sodium hydroxide (7 ml.) was added with stirring until all the solid had dissolved (pH 14). The solution was added to boiling water (30 ml.) containing acetic acid (3 ml.). The mixture was boiled briefly and allowed to stand at room temperature for one hour. The product was filtered off, washed with water, and dried under vacuum overnight to give 6.88 g. of the desired product;
m.p. about 240C. (dec.).
Anal. calc~d. for C5H4N5I 0.014 H2O:
C, 22.99; H, 1.55; N, 26.81; I, 48.57;
H2O, 0.10 Found: C, 23.32; H, 1.52; N, 26.75; I, 48.14 H20, 0.09.
b) 6-Iodo-9H-Durin-2-amine ion (~-). triethyl-(~henvlmethyl)ammonium(l:l) salt Benzyltriethylammonium hydroxide (24.6 ml., 43.3 mmole, 40 wt % in methanol) was added to a suspension of 6-iodo-9H-purin-2-amine (10.0 g., 38.3 mmole) stirred in absolute ethanol (22 ml.) until nearly all of the suspension had dissolved. Additional 6-iodo-
3 3 GY26a 9H-purin-2-amine (0.4 g.) was added and the mixture was stirred for 15 minutes. The excess 6-iodo-9H-purin-2-amine was filtered off, washed with absolute ethanol, and the filtrate evaporated until no more ethanol was observed on the condenser. The residue was rapidly stirred while ethyl acetate (25 ml.) was added all at once. A solution was formed from which a solid precipitated. Additional ethyl acetate (175 ml.) was added dropwise over 30 minutes. After precipitation was complete, the mixture was stirred for 2 hours, filtered, washed with ethyl acetate, and dried under vacuum to give 15.16 g. of the desired salt product; m.p. 156-159 C. (effervescent).5 Anal. calc~d. for C18H25N5I . 0.065 H2O . 0.02 starting material:
C, 47.39; H, 5.54; N, 18.63; I, 28.22;
H2O, 0.26 Found: C, 47.45; H, 5.50; N, 18.89; I, 27.94;
H2O, 0.26.
c ) r ls-(la.2~3a)1-3-(2-Amino-6-iodo-9H-purin-9-vl) 1,2-cyclobutanedimethanol. dibenzoate ester Trifluoromethanesulfonic anhydride (4.02 ml., 24.0 mmole) in dry methylene chloride (4 ml.) was added dropwise over 5 minutes to a solution of [lS-(la,2~,3~)]-3-hydroxy-1,2-cyclobutane-dlmethanol, dibenzoate ester (6.80 g., 20.0 mmole) and pyridine (2.56 ml., 30.0 mmole) in methylene chloride (30 ml.) chilled in an ice-bath. After 20 minutes, the reaction was quenched with ice, washed into a separatory funnel with methylene chloride, and washed with cold water (2 x 30 ml.), 5% sodium bisulfate (30 ml.), and water (30 ml.). Each aqueous layer was rinsed with a few mls. of methylene chloride which were added to the previous layer. The methylene GY26a chloride layer was dried with magnesium sulfate with stirring for 5 minutes. The mixture was filtered and the magnesium sulfate was washed three times with methylene chloride. The total volume of the methylene chloride filtrate was about 75 ml. (about 0.25 M in trifluoromethane-sulfonate).
6-Iodo-9H-purin-2-amine, ion (1 ), triethyl-(phenylmethyl)ammonium (1:1) salt (10.49 g., 22.0 mmole) was added and the suspension was stirred at room temperature. After 6 hours the mixture was filtered, the filter cake was washed with methylene chloride, and the filtrate evaporated. The residue was taken up in water (50 ml.) and ethyl acetate (100 ml.). The aqueous layer was separated, and the ethyl acetate layer was washed with water l3 x 50 ml.), 30%
phosphoric acid (2 x 10 ml.), water (50 ml.), a mixture of 5% aqueous sodium bicarbonate (30 ml.) and brine (20 ml.), and brine (10 ml.). The organic layer was dried over magnesium sulfate for 5 minutes and 10 g. of charcoal (Dacro, fine mesh) was added.
The mixture was stirred for 15 minutes, filtered through Celite, and the filter cake was washed 5 times with ethyl acetate. The filtrate was evaporated to a foam (11.67 g.). The residue was evaporated from a mixture of methylene chloride (10 ml.) and absolute ethanol (10 ml.) to form a solid. This solid was heated on the steam bath to boiling with absolute ethanol (80 ml., 7 ml./g. foam) for 2 minutes. The mixture was kept at room temperature for 3 hours, filtered, and washed twice with cold 95% ethanol.
The solid was dried under vacuum overnight to give 8.07 g. of the desired product; m.p. 148 - 149C., [a]D = -20.5 (c = 1, chloroform). TLC (silica gel, ethyl acetate, Rf = 0.65).

.

2~9~33 GY26a 25 22 54 0.06 H2O 0.02 C, 51.38; H, 3.83; N, 11.96; I, 21.68;
H2O, 0.18 5 Found: C, 51.19; H, 3.77; N, 11.89; I, 21.86;
H2O, 0.18.
d) ~lR-(la~2~.3a)~ Amino-9-r2~3-bis(hydr methyl)~yc1Obutyll-~ d1hvdro-6H-purilL-6-Q~
A solution of sodium methoxide (5.3 ml., 3.9 M
prepared from sodium/methanol) was added by syringe to a suspension of [lS-(la,2~,3a)]-3-(2-amino-6-iodo-9H-purin-9-yl)-1,2-cyclobutanedimethanol, dibenzoate ester (8.0 g., 13.7 mmole) in dry methanol (40 ml.).
The mixture was refluxed for 1.5 hours. The solution was neutralized with lN HCl (10.1 ml.) to pH 7. The methanol was evaporated to give a reaction mixture containing [lS-(la,2~,3a)]-3-(2-amino-6-methoxy-9H-purin-9-yl)-1,2-cyclobutanedimethanol.
This aqueous mixture was washed into a separatory funnel with water (2 x 8 ml.) and acidified with concentrated HCl (3.6 ml., 43.9 mmole) to pH of about 0.5. The mixture was washed with methylene chloride (3 x 15 ml.) to remove methylbenzoate and the aqueous layer was rotary evaporated for a few minutes to remove any residual methylene chloride. The aqueous layer was heated in a 95 oil bath for 3 hours. Sodium hydroxide (10.6 ml., 4N) was added to adjust the pH to 7. Crystals formed immediately. The mixture was allowed to cool to room temperature slowly. After standing overnight at room temperature, the mixture was chilled at 0 C.
for one hour, filtered, and washed with cold water.
The wet product was washed into a 250 ml. flask with 35 ml. of water. The mixture was heated to boiling 209~n33 GY2 6a and 30 ml. of water was added to dissolve all of the product. The solution was kept at room temperature for 3 hours and at 0~ c. for one hour. The crystals were filtered, washed with cold water, and dried 5 under vacuum over phosphorus pentoxide to give 3.~ g.
of the desired product; m.p. about 290 C. (dec.), [a]D = - 24.4 (c = 1, dimethylsulfoxide), +25.3 (c = 1, 0.1 N sodium hydroxide). TLC (silica gel;
tetrahydrofuran, methanol, ammonium hydroxide, 6:3:1, lO Rf = 0.45).

c, 46.51; H, 6.06; N, 2~1.65; H2O, 6.60 Found: c, g6.71; H, 6.02; N, 24.88; H2O, 6.62.

Exam~le 2 Ll~= ~la. 2~. 3a) 1-3- (2-Amino-6-i~do-9H-Durin-9-ylL~2 cyclo~u~ane~methanol. dibenzoate ester a) 6-lodo-9H-~urin-2-amine ion (1-), tet~abut~l~mmonium (1:1) sal~
6-Iodo-9H-purin-2-amine (133 g., 510 mmole) ground up in a mortar and pestle was washed into a 2 liter pot with 1.5 liter dichloromethane. Aqueous tetrabutylammonium hydroxide (1.53 M, 333 ml., 510 mmole) was added and the mixture was stirred 25 mechanically for 30 minutes. The mixture was then filtered through Celite, washed five times with methylene chloride, and the methylene chloride layer was separated, dried (MgSO4), and evaporated. The residue was evaporated from toluene (300 ml.). The 30 residue was taken up in 1 liter of ethyl acetate and heated briefly to form a two-phase mixture. This mixture was stirred mechanically at room temperature for 30 minutes. The resulting crystals were filtered, washed with ethyl acetate, and dried under ~0~80~3 GY26a vacuum overnight to give 213.5 g. of product. 20 g.
of this material was dried further overnight at 50 C. under vacuum over phosphorus pentoxide to give 6-iodo-9E~-purin-2-amine, ion (1 ), tetrahutylammonium (1:1) salt; m.p. 114 - 116 C.
Anal, Calc'd. for C5H3IN5 . C16H36 2 C, 49.96; H, 7.84; N, 16.65i I, 25.14;
H2O, 0.46 Found: C, 50.17; H, 7.91; N, 16.86; I, 25.33;
H2O, 0.48.
b) ~lS=lla.2~.3a)~ 2-Amino-6-iodo-9H-Durin-9-yl)-1.2-cvclo~utanedlmethanol~ dibenzoate ester [lS- (la, 2~,3~)]-3-Hydroxy- 1,2-cyclobutane-dimethanol, dibenzoate ester (3.40 g., 10.0 mmole) was dissolved in methylene chloride (15 ml.) and chilled in an ice bath. Pyridine (1.28 ml., 15.0 mmole) was added. Trifluoromethanesulfonic anhydride (2.01 ml., 12.0 mmole) was added by syringe to methylene chloride (3 ml.) in a dropping funnel. The trifluoromethanesulfonic anhydride solution was added dropwise to the cold reaction mixture over 5 minutes.
After a total of 25 minutes, the reaction was worked up at a temperature below 20 C. The reaction mixture was quenched with ice and diluted to 100 ml.
with methylene chloride. The organic layer was washed with 25 ml. of each of ice-water (twice), cold 5% sodium bisulfate, and ice water. Each organic layer was backwashed with 2 ml. of methylene chloride. The combined organic layers were dried over magnesium sulfate. After filtration, the solution was evaporated down to a mobile oil in a bath of ice water.

~`93~33 G~26a 6-Iodo-9H-purin-2-amine, ion (1 ), tetra-butylammonium (1:1~ salt (6.02 g., 12 mmole, dried over phosphorus pentoxide under vacuum at 50 c., 0.13 M% water) was dissolved in methylene chloride (7 ml.) and chllled in an ice bath. The above trifluoromethanesulfonyloxy material was washed into this solution with methylene chloride (5 x 1 ml.).
After 30 minutes, the ice bath was removed and the reaction mixture was stirred overnight at room temperature. A precipitate formed. The methylene chloride was evaporated and the residue was taken up in ethyl acetate (50 ml.) by brief heating on a steam bath. The mixture was diluted with toluene (50 ml.), washed with 30% phosphoric acid (25 and 10 ml.), and water (6 x 150 ml.). The organic layer was then washed with 5% sodium bicarbonate (50 ml.) and brine (50 ml.) and then dried (magnesium sulfate).
Charcoal (Darco, 5 g.) was added to the dry solution, stirred for 30 minutes, and filtered through Celite. ~.
The filter cake was washed wi~h ethyl acetate (5 x 10 ml.). The filtrate was evaporated to give 5.51 g. of crude product.
The residue was heated to boiling with absolute ethanol (90 ml.) on the steam bath. The product formed an oil on heating which crystallized in the boiling mixture. The hot mixture was allowed to cool to room temperature and allowed to stand for 4 hours and then kept at 0 C. overnight. The crystals were filtered, washed with cold 95% ethanol (2 x 20 ml.), and dried under vacuum to give 4.43 g. of material, m.p. 148 - 149 C.
This material (1.0 g.) was dissolved in methylene chloride (3 ml.) and diluted with absolute ethanol (10 ml.). The solution was evaporated under 209803~
GY26a vacuum until it had become cloudy. It was heated briefly on the steam bath and kept at room temperature ~or 2 hours. After being kept at 0 C.
overnight, the product was filtered, washed twice with cold 95% ethanol, and dried under vacuum to give 0.946 g. of the desired product; m.p. 149 - 150 C., [a]D = -20.5 (c = 1, chloroform). TLC (silica gel;
ethanol, Rf = 0.59).
Anal. calc~d. for C2sH22INso~ . 0.13 H2O . 0.15 C2HsoH:
C, 51.28; H, 3.94; N, 11.82; I, 21.41;
H2O, 0.4 Found: C, 51.46; H, 3.75; N, 11.76; I, 21.09;
H2O, 0.4.
Example 3 15 rls~ 2~3a)l-3-(2-Amino-6-methoxv-9H-purin 1,2-cyclo~ nçdimethanol An analytically pure sample of this intermediate was prepared as follows.
A suspension of [lS-(la,2~,3a)]-3-(2-amino-6-iodo-9H-purin-9-yl)-1,2-cyclobutanedimethanol, dibenzoate ester (2.915 g., 5 mmole) and sodium methoxide (0.35 ml., 4.63 M in methanol, 1.62 mmole) in methanol (20 ml.) was stirred under nitrogen at room temperature. After 3.5 hours a clear solution was obtained. After 4.5 hours, sodium methoxide (1.5 ml., 4.63 M in methanol, 6.9 mmole) was added and the mixture was heated at 65 C. for 5 hours.
The mixture was cooled to room temperature and acetic acid was added (0.48 g., 8 mmole, pH about 8.5 measured with electrode and about 5 with wet pH
paper). The solvent was evaporated under vacuum and the residue was heated in acetone (15 ml.) and filtered. The insoluble material was washed with acetone (5 ml.). The solvent was removed from the 2~98~3 GY26a filtrate and the residue was washed three times with hexane (5 ml.). The insoluble portion was redissolved in hot acetone (15 ml.). The product crystallized out. After standing overnight in an ice bath, the solid was filtered, washed with acetone (5 ml.), and dried under vacuum over phosphorus pentoxide for three hours to give 1.04 g. of crude product. After 2 days a second crop (0.236 g.) of product was obtained from the mother liquors. These two crops were combined and 1.236 g. of impure product was dissolved in hot ethyl acetate (15 ml.).
Silica gel ~EM-60, 60 g.) was added and the solvent was removed on a rotary evaporator. This adsorbed material was then charged on a silica gel column 15 (about 25 x 250 mm) and eluted successively with ethyl acetate (100 ml.), 10% ethanol in ethyl acetate (1700 ml.), and 20% ethanol in ethyl acetate (1100 ml.). The TLC homogeneous fractions were combined and the solvent was removed to give 0.7 g. of the desired product. The solid was heated in acetone (15 ml.) and allowed to stand at room temperature for 7 hours. The product was filtered, washed with acetone and dried over phosphorus pentoxide under vacuum for 15 hours to give 0.55 g. of the desired product; m.p.
25 144 - 145 C.; [a]D = -21.4 (c=1, dimeth~l-sulfoxide). TLC(silica gel; ethanol:hexane, 1:1, Rf = 0.5).
Anal. calc'd. for C12H17N5O3:
C, 51.61; H, 6.13; N, 25.07 Found: C, 51.52; H, 6.07; N, 25.28.

GY26a ExamDle 4 ~lR- (la,~ 2-Amin~-9-~2.3-his(h!~roxymethyl)-cyclo~utyll-1.9-dihydro-6H-Durin-6-one a~ 6-Chloro-9H-Durin-2-amine, iQaL1-) tetra-butylammQ~ium (1~ al~
An aqueous solution of tetrabutylammonium hydroxide (1.53 M, 2.5 ml., 3.83 rnmole) was added dropwise to a slurry of 6-chloro-9H-purin-2-amine (1.69 g., 10 mmole) in methylene chloride (40 ml.) at ambient temperature. After 10 minutes the biphasic solution was filtered with suction through a sintered glass funnel to remove a small amount of undissolved solid. The filtrate was transferred to a separatory funnel and the organic layer was separated, dried over magnesium sulfate, and filtered. The filtrate was evaporated under vacuum and the residue was triturated with ethyl acetate (20 ml.) and filtered.
The product was dried under vacuum over phosphorus pentoxide at ambient temperature for 5 hours to give 20 3.41 g. of desired product; m.p. greater than 89 C.
Anal. calc'd. for C21H3gN6Cl 0.65 H2O:
C, 59.66; H, 9.61, N, 19.88; Cl, 8.39;
H2O, 2.79 Found: C, 59.22; H, 9.88, N, 19.86; C1, 8.74;
H2O, 2.77.
b) ~lS- (la,2~,3a) l-3-(2-Amino-6-chloro-9H-pu~in-9-yl)-1~2-c~clobutanedimethanol dibenzoate ester A solution of trifluoromethanesulfonic anhydride (5.97 ml., 35.5 mmole) in dry methylene chloride (10 ml.) was added dropwise over 5 minutes to a solution of [lS-(1~,2~,3~)]-3-hydroxy~1,2-cyclobutane-dimethanol, dibenzoate ester (10.06 g., 29.6 mmole) and pyridine (3.7 ml., 44.4 mmole) in methylene chloride (45 ml.) chilled in an ice bath. After 20 2~033 GY26a minutes the reaction was quenched with ice, washed into a separatory funnel with methylene chloride, and washed with ice cold water (2 Y~ 100 ml.), 5% sodium bisulfate (150 ml.), and ice cold water (100 ml.).
Each aqueous layer was washed with methylene chloride (10 ml.) which was added to the previous methylene chloride layer. The slightly colored and turbid methylene chloride layer was dried with magnesium sulfate by stirring for 20 minutes and filtered to give an almost clear solution. The solvent was evaporated to 25 ml. and then the solution was diluted to 101 ml. with dry methylene chloride to give a 0.29 molar solution of trifluoromethane-sulfonyloxy compound. The solution was stored over magnesium sulfate under argon at -20 C.
6-Chloro-9H-purin-2~amine, ion (1-), tetra-butylammonium (1:1) salt (2.47 g., 6 mmole) was added to the above trifluoromethanesulfonyloxy compound (17.2 ml., 0.29 M in methylene chloride, 5 mmole) and the suspension was stirred at room temperature. After 6 hours the reaction flask was stored at -20 C.
overnight. After warming to room temperature, the mixture was filtered. Baker silica gel (60 - 200 mesh, 10 ml.) was added to the filtrate and the solvent was evaporated under vacuum. The solid was charged on a silica gel column (25 x 260 mm., prepared in 25% ethyl acetate in hexane). The product was eluted successively with 25%, 50~, and 75% ethyl acetate in hexane (100 ml. each) and ethyl acetate 30 (300 ml.) collecting 50 ml. fractions. Fractions 9 - 12 (TLC, silica gel, ethyl acetate, Rf = 0.56) were combined and evaporated to give 1.54 g. of desired product.

209~033 - 31 - GY26a c ) LlS- (la. 2~. 3a) 1-3- (2-Ami~o-6-chlo~o-9H-purin-9-yl)-1.2-cyclo~ imeth~nQl A solution of sodium methoxide (0.39 M in methanol, 0.081 ml., 0.32 mmole) was added by syringe to a suspension of [lS-(la,2~,3a)]-3-(2-amino-6-chloro-9H-purin-9-yl)-1,2-cyclo-butanedimethanol, dibenzoate ester (1.54 g., 3.14 mmole) in dry methanol (20 ml.). After stirring for 2 hours at room temperature the mixture was stored for 2 days at -20 C. The product crystallized during further stirring at room temperature for 2 hours. The mixture was allowed to stand at 0 C. for 3 hours.
The solid was filtered, washed with cold methanol, and dried under vacuum to give 0.52 g of desired product; m.p. 198 - 201 C. TLC (silica gel;
ethanol:ethyl acetate, 1:9, Rf = 0.49).
Anal. calc~d. for CllH14ClN5O2:
C, 46.43; H, 4.99; N, 24.61; Cl, 12.46;
H2O, 0.30 0 Found: C, 46.81; H, 5.01; N, 24.24; Cl, 12.54;
H2O, 0.36.
d) ~lR- (la, 2~.3a)l-2-Amino-9-r2.3-bis(hvdr methyl)-cyclobutyll-l.9-dihydro-6~-~urin-6-one A mixture of [lS-(la,2~,3a)]-3-(2-amino-6-chloro-9EI-purin-9-yl)-1,2-cyclobutanedimethanol and 2N HCl was heated under nitrogen at 95 C. After one hour the mixture was neutralized with 4N sodium hydroxide (about 0.6 ml.) and a few drops of lN
sodium hydroxide to a pH of about 8Ø A thick white precipitate formed. The mixture was stirred in an ice bath for about 1.5 hours, filtered, washed with ice cold water (2 ml.), and dried over phosphorus pentoxide under vacuum to give the desired product.

, ~'' ;

209~033 GY26a rls- (la. 2@,~l-3-~2-~mino-6-iodo-9H-Durln-9-Y1)-1,2-Cyclob~t~n~Lmg¢hd~LL~ dibenzoatç ester a) rls- (1~. 2~, 3~1-3- r r (~-Nitrophenyll-s~lfonyll-S oxyl-1 ~-cyclobutanedime~hanol dibenzQate ester p-Nitrobenzenesulfonylchloride (5.9 g., 29.0 mmole) was added to a solution of [lS-(la,2~,3~)]-3-hydroxy-1,2-cyclobutanedimethanol, dibenzoate ester 6.8 g., 20.0 mmole) in pyridine (20 ml.). After stirring overnight at room temperature, water (8 ml.) was added and the mixture was stirred for one hour.
The pyridine was evaporated off and the residue was treated with ethyl acetate (150 ml.). The mixture was washed successlvely with water, 1% hydrochloric acid, water, 5% sodium bicarbonate, water, and brine.
The solution was dried (MgSO4), stirred for 15 minutes with activated charcoal, and filtered through Celite. The solvent was evaporated to give 8.7 g. of crude product. This crude solid was triturated with ether (25 ml.) and then stirred for one hour. The product was filtered, washed with ether, and dried under vacuum to give 7.89 g. of [lS-(la,2~,3~)]-3-[[(4-nitrophenyl)sulfonyl]oxy]-1,2-cyclobutane-dimethanol, dibenzoate ester; m.p. 100 - 101C.5 Anal. calc'd. for C26H23NOgS 0.11 H2O:
C, 59.19; H, 4.44; N, 2.65; S, 6.08;
H2O, 0.39 Found: C, 59.17; H, 4.02; N, 2.61; S, 6.19;
H2O, 0.39.
b) rls- (la,~,3~)l-3-(2-Amino-6-iodo~H-purin-9-yl)-1.2-cyclob~_nedimethan~l~ dibenæoate ester 6-Iodo-9H-purine-2-amine, ion (1-), triethyl-(phenylmethyl)ammonium (1:1) salt (4.97 g., 11.0 mmole) was added to a solution of the product from . ~

209803~
G 6a part (a) (5.25 g., 10.0 mmole) in acetonitrile (20 ml.) and the mixture was ~efluxed for 8.5 hours. The solvent was evaporated and the residue was taken up in ethyl acetate (200 ml.). The solution was washed with water (4 x 200 ml.), dried (MgSO4), and the solvent was evaporated. The crude product was purified by flash chromatography over silica gel (25 x 200 mm. column). The product was eluted successively with 500 ml. each of 10%, 30%, 60%, and 80% ethyl acetate in hexane followed by ethyl acetate (500 ml.). Product containing fractions were combined and evaporated to give 3.73 g. of desired product.
Example 6 ~lR-( la . 2~, 3a) 1 -2 -Amino-9-~2, 3 -bis(hvdroxvmethvl)_ cvclobutyll-1.9-dihydro-6H-purin-6-one a) rlR- (la, 2~, 3a) 1 -2-Amino-9- ~2, 3-bis~(benzovl-oxv)methyllcyclobutyll-1.9-dihydro-6H-Durin-6-one A mixture of [lS- (la, 2~, 3a) ] -3- (2-amino-6-iodo-9H-purin-9-yl)-1,2-cyclobutanedimethanol, dibenzoate ester (1.755 g., 3.0 mmole) and 57% aqueous acetic acid was heated to 100C. under a nitrogen atmosphere. After 4.5 hours, the solutlon was cooled and treated with sodium bicarbonate (252 mg., 3.0 mmole). The solvent was evaporated on a rotar~
evaporator and the residue was dried for one hour under vacuum. The solid was treated with water (10 ml.), filtered, and washed with water. The product was dried under vacuum overnight. The solid was 30 slurried in aqueous sodium bicarbonate (10 ml.).
After stirring for 45 minutes, the solid was filtered, washed with water, and dried under vacuum over phosphorus pentoxide to give 1.4 g. of crude product.

20~33 GY26a A solution of the crude product in ethyl acetate was charged on a silica gel column (200 ml., prepared in hexane). The column was eluted successively with 100 ml. of ethyl acetate, 1.5 l~ 10% methanol in ethyl acetate, and 500 ml. of S0% methanol in ethyl acetate. Fractions were collected (about 35 ml.
each) as soon as the yellow band on the column started to elute. Fractions 3 to 17 gave 1.1 g. of product as a light yellow solid. An analytical sample was obtained by crystallization from ethyl acetate followed by recrystalization from acetone/water to give pure product; m.p. 160 -161C.; [~]D = -11.5 (C = 1, dimethylformamide).
TLC (silica gel; methanol: methylene chloride, 1:9, lS Rf = 0.43).
Anal. calc~d. for C25H23NsO5 ~ 0.5 H2O:
C, 62.23; H, 5.01; N, 14.S2; H2O, 1.87 Found C, 62.00; H, 4.68; N, 14.56; H2O, 1.59.
b) ~lR-(la,2~,3~)l-2-Amino-9-~2,3-bis(hvd~Q~y~
methyl)cvcLobutyl~ 9-dihyd~-6H--D-urin-6-one A suspension of the product from part (a) (95 mg., 0.2 mmole) in agueous sodium hydroxide (1 ml., lN) was heated under argon at 100 C. in an oil bath, After 3 hours, the mixture was cooled to room temperature and acidified with lN hydrochloric acid to pH 3. Benzoic acid partly crystallized out during acidification. The mixture was washed with methylene chloride (3 x 2 ml.) to remove the benzoic acid. The pH of the aqueous layer was adjusted to 6 with lN
sodium hydroxide. The agueous solution (total volume about 7 ml.) was concentrated to about 4 ml. on a rotary evaporator. The product was crystallized out during evaporation. The flask was cooled in an ice bath. After 3 hours, the product was filtered, 2 0 9 8 0 3 3 GY26a washed with ice-cold water and dried over phosphorus pentoxide under vacuum to give 48 mg. of desired product as white crystals; m.p. greater than 280 (dec.).
Alternatively, the desired final product was also prepared as follows:
A suspension of the product from part (a) (95 mg., 0.2 mmole) in methanolic sodium methoxide (2 ml., 0.2 M) was refluxed under argon in an oil bath.
After 2.5 hours, the mixture was cooled to room temperature and the solvent was evaporated. The residue was treated with 1.5 ml. of lN hydrochloric acid. The mixture was washed with methylene chloride (3 x 2 ml.) to remove methyl-benzoate. The pH of the aqueous layer was adjusted to 6 with lN sodium hydroxide. The product crystallized out in a few minutes. The flask was cooled in an ice bath. After 3 hours, the product was filtered, washed with ice cold water, and dried over phosphorous pentoxide under vacuum overnight to give 42 mg. of product as pale yellow crystals; m.p. 275 (dec.).

r3S- (3a 5,B 6~)l-2-Amino-1.9-dihydro-9-rtetrahYdro-5-hvdroxy-6-(hydroxymethyll-2~yl;an-3-yll -6H-purin-6-Q~
a) !~R-trans)-3-(Acetyloxy) -3,4-dihydro-2H-pyran-2-methanol. acetate (ester) A suspension of sodium borohydride (3.14 g., 83.0 mmole) in anhydrous tetrahydrofuran (226 ml.) and 1,2-dimethoxyethane (113 ml.) was refluxed for l.S hours. After cooling, copper(I)bromide (297 mg., 2.07 mmole) was added and the mixture was refluxed for 2 hours. To this slurry was added tri-O-acetyl-D-glucal (11.30 g., 41.53 mmole) and tetrakis-, ' 20~8033 GY26a ~triphenyl phosphinelpalladium(O) (2.39 g., 2.076 mmole) at room temperature. The mixture was stirred at room temperature overnight, and then heated at 505 C. for 5 hours. The reaction mixture was then cooled to room temperature , treated at 0C. with saturated sodium bicarbonate (11 ml.) and 30% hydrogen peroxide (22 ml.). The reaction mixture was diluted with ethyl acetate, washed with saturated sodium bicarbonate, dried and concentrated n ~ç~Q. The residue was purified by column chromatography on silica gel, eluting with ethyl acetate (5% to 10%)-hexane with 0.1% triethylamine to give the title compound as a white solid (2.18 g., 10.18 mmole).
b) ~2R-(2a,3~. 5~). F -2- r ~Acetyloxy~methylltetrahydro-2H-~yran-3.5-diol, 3-acetate A 1.0 M borane-tetrahydrofuran complex (9.59 ml., 9.59 mmole) was added dropwise at 0C under nitrogen to a dry tetrahydrofuran solution (22 ml.) of the product from part (a) (2.055 g., 9.59 mmole).
After 2.5 hours, the mixture was treated with saturated sodium bicarbonate (9 ml.) and 30% hydrogen peroxide (4.3` ml.) at 0-5C. and stirred for 2 hours. The reaction mixture was cooled to 0C., diluted with ethyl acetate, washed with sodium bicarbonate, dried and concentrated n vacuo. The crude product was purified by column chromatography on silica gel, eluting with ethyl acetate (50%, 75%) - hexane, to yîeld the title compound as a colorless oil (0.654 g., R~ = 0.44) and the epimeric alcohol, 30 [2R-(2~,3~,5~)]-2-[(acetyloxy)-methyl]tetrahydro-2H-pyran-3,5-diol, 3-acetate, as a white crystalline solid (0.325 g., Rf = 0.34).

20~33 GY26a c) r2R- (2~,3~.5a)l-3-(Acetvloxv)-5-(2-amino-6-iodo-9H-p~rin-9-vl)tetrahy~rQ-2H-~yran-2-methanol~ acetate (ester) To a mixture of 6-iodo-2-aminopurine (1.21 g.,
4.637 mmole) in methylene chloride (12 ml.) at room temperature, was added 1.5 M tetra(n-butyl)ammonium hydroxide (2.7 ml., 4.05 mmole). The reaction mixture was stirred for 10 minutes, and the volatiles were removed ~n vacuo. Methylene chloride (12 ml.) was added to the white residue, and the resulting solution was dried (magnesium sulfate), filtered, and the filtrate was concentrated ~ vacuo to yield the tetra(n-butyl)ammonium salt of 6-iodo-2-aminopurine as a white residue.
To a stirred solution of [2R-(2a~3~5~)]-2-[(acetyloxy)methyl]tetrahydro-2H-pyran-3,5-diol, 3-acetate (0.633 g., 2.72 mmol) in methylene chloride (12 ml.~ at -20c. was added pyridine (0.33 ml., 4.09 mmole) and trifluoromethanesulfonic anhydride (0.504 ml., 3.0 mmole). The reaction was warmed to room temperature. The mixture was diluted with methylene chloride, washed with 10% sulfuric acid, saturated sodium bicarbonate, and water. The organic layer was separated, dried, and concentrated in vacuo to yield crude trifluoromethanesulfonyl product as a dark pink oil.
A solution of this trifluoromethanesulfonyl product in methylene chloride (4 ml.) was added to a mixture of the tetra(n-butyl) ammonium salt of 6-iodo-2-aminopurine in methylene chloride (10 ml.) and the reaction was stirred at room temperature for 16 hours. The mixture was concentrated in vacuo. The residue was dissolved in ethyl acetate (120 ml.) and water (120 ml.), treated for 2 hours with AG-MP 50 GY26a cation resin ~sodium+ form, 30 g.~, and filtered through Celite~. The crude product was purified by column chromatography on silica gel, eluting wlth ethyl acetate (50%,75%,100)-hexane, to yield the title compound as a foamy yellow solid (O.S87 g., 1.235 mmole).
d) r 3S-L~L 5~,6a)l-2-Amino-1L~-dihydro-9-rtetrahy~d~Q-~=hvdroxy-6-(hvdroxymethyl)-2H=~Yran-3-Yll-6H-Durin-6-one Sodium methoxide solution (0.43 M, 4.22 ml.) was added to a solution of the product from part (c) (0.58 g., 1.2 mmole) in methanol (5 ml.). The mixture was stirred at room temperature for 45 minutes and then refluxed for S hours. After cooling lS to room temperature, the pH of the mixture was adjusted to 7.0 by the addition of lN hydrochloric acid (1.4 ml.), and concentrated ln vacuo.
Additional lN hydrochloric acid (2.S ml.) was added to the residue and this mixture was heated at 50C
20 for 18 hours and then at 85C for 3 hours. The reaction mixture was cooled to room temperature, diluted with water, and the pH adjusted to 7.0 by the addition of 3N sodium hydroxide (0.8 ml.). The mixture was concentrated n vacuo and the residue was 2S subjected to a CHP-20 column, eluting with a continuous gradient (water to 2S% acetonitrile in water), to afford a yellow residue. This crude product was triturated in methylene chloride, recrystallized from hot water, and treated with activated charcoal to yield 48 mg. of the title compound as white crystals; [a]D = -3.46 (c =
0.0866, dimethylsulfoxide).

20~33 GY26a H NMR (270 NHz, DMSO-d6): ~ 10.57 (s, lH,-NH);
(s,lH,C8H); 6.47 (s,2H,-NH2); 4.92 (d, J=5.28~z, lH);
4.67-4.62 (t,J=5.86Hz, lH); 4,52(s,1H);
4.06(d,J=2.34Hz,lH); 3.83-3.78 (dd,J=2.34Hz,12.3Hz, lH); 3.66(m,lH); 3.5 (m,lH); 3.16 (m,lH); 2.51 (m,lH); 2.20 (m,lH); 1.85-1.79 (m,lH).
1.R. (Ksr pellet): 3435, 3194,2648,2903,1697,1639, 1606,1398,1180,1066 cm~l.
Anal. calc'd. for CllH15N5O4 0.36 H2O:
C, 45.90; H, 5.51; N, 24.33 Found: C, 46.07; H, 5.06; N, 24.16.
ExamDle 8 r3S-f3~4~l5a)l-~-Amino~ -~ hvdro-9-~tetrahy~o=
4.5-bis(hydr_xymethyl)-3-furany~l-6H-~urin-6-one a) r3~ $Ll-6-Iodo-9-rtetrahydro-4,5-bisr(~henvlmethoxv~methvl~-3-furanvll-9H-~urin-2-amine A mixture of [3R- (3a, 4~,5~)]-tetrahydro-4,5-bis[(phenylmethoxy)methyl]-3-furanol, 4-methyl-benzenesulfonate ester (54.24 g., 112.5 mmole, prepared as described in Example 1 of U.S. Patent
5,059,690) and 6-iodo-9~1-purin-2-amine, ion (1-), tetrabutylammonium (1:1) salt (89.1 g., 177.5 mmole) in anhydrous dimethylformamide (600 ml.) was heated under nitrogen at 85 - 90 C. for 12 hours. The yellow solution was parti~ioned between water (1.5 l.) and ethyl acetate (1.5 1.). The organic layer was dried (sodium sulfate) and evaporated to give 66 g. of an oil. Chromatography on 5 l. of silica gel (K-60) in ethyl acetate/hexane (2/1) afforded 31.2 g.
of the product (Rf = 0.42, ethyl acetate/hexane, 2/1), which gave a crystalline product on standing;
m.p. 84 - 86 C.

2098~33 GY26a b) ~ l~a)l-6-Methoxv-9-~etrahvdro-4~5-bis r (phenylme~Qxy~m~hyll-~-furany~ 9~-Durin-2-amine A solution of the product from part (a) (31.2 S g., 54.64 mmole) in warm methanol (500 ml.) was treated all at once with 10% sodium hydroxide (50 ml.), and then was heated for one hour on a steam cone. The pH was adjusted to 7 with 10~ hydrochloric acid (45 ml.) and the mixture was evaporated to a gum. This was partitioned between ethyl acetate and water, the organic layer was dried (sodium sulfate), and evaporated to give 24.9 g. of product as a foam.
TLC (silica gel; ethyl acetate) Rf = 0.57.
c) r3s-(3~ .5a)l-6-Methoxv-9-r~e~rahvdro-4~5 bis(hvdroxvmethvl)-3-furanvll-9H-purin-2-amine All of the product from part (b) was covered with 95% ethanol (800 ml.), 20 g. of 20% palladium hydroxide on carbon catalyst was added, followed by cyclohexene (400 ml.). The mixture was refluxed at 20 85 - 90 C. for 2 hours. The catalyst was filtered on Celite~ and the filter cake was washed with methanol (300 ml.). The filtrate was evaporated to give 17.8 g. of the product as an oil. TLC (silica gel; chloroform:methanol:ammonium hydroxide, 6:3:1) 25 Rf = 0.75.
d) r3s-(3a 4~.5a)l-2-Amino-l~9-dihydro-9-rtetrahydro-4,5-ki~hvdr_~ymç~hyl)-3-furanyll-6H-Durin-6-one All of the crude product from part (c) was dissolved in lN hydrochloric acid (200 ml.) and heated at 70 - 75 C. for 10 hours under nitrogen.
The resulting solution was cooled to room temperature and filtered through a Celite~ pad. The filtrate was basified to pH of about 8 by the addition of 20 ml.

209~0~

GY26a of concentrated ammonium hydroxide. The resulting white slurry was heated on a hot plate until dissolved, then allowed to come to room temperature over 2 hours. The mass of solid was filtered and S washed with water (75 ml.), dried as much as possible, and the filter cake was washed with 200 ml.
of acetonitrile and finally with 200 ml. of ether.
Drying in vacuo gave 11.6 g. of solid, m.p. 240 -245 C., which was 99% pure by electrochromatography.
This material was combined with 1.1 g. of product from a smaller run and recrystallized by dissolving in hot water (200 ml.), filtering hot (rapidly), and cooling to room temperature in an ice-bath. The solid was filtered and washed with 100 ml. of cold water. Drying n vacuo over phosphorus pentoxide for 18 hours gave 10.96 g. of product as a white solid;
m.p. 270 - 27~ c. [a]D = -46.8 (c = 0.22, dimethylsulfoxide).
Anal. c~lc'd. for CllHlsNsO~ 0.23H20 0.088NH4Cl:
C, 45.54; H, 5.49; N, 24.57; Cl, 1.08 Found: C, 45.54; H, 5.40; N, 24.23; Cl, 1.08.

Claims (14)

What we claim is:
1. A compound of the formula wherein:
Y1 is chloro, bromo, or iodo;
R1, R2, R3, and R4 are independently selected from the group consisting of straight or branched chain alkyl of 1 to 10 carbons and substituted straight or branched chain alkyl of 1 to 10 carbons;
substituted straight or branched chain alkyl of 1 to 10 carbons refers to such alkyl groups having one, two, or three substituents selected from the group consisting of alkoxy of 1 to 6 carbons and aryl;
aryl refers to phenyl and phenyl having one, two, or three substituents selected from the group consisting of alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, chloro, bromo, iodo, and fluoro.
2. The compound of Claim 1 wherein:
Y1 is iodo; and R1, R2, R3 and R4 are each n-butyl; or Y1 is iodo; and R1, R2, and R3 are each ethyl and R4 is benzyl;
or Y1 is chloro; and R1, R2, R3, and R4 are n-butyl.
3. A process for preparing the cyclobutyl purine of the formula which comprises reacting a purine salt of the formula with the bis (2,3-protected hydroxymethyl)cyclo-butane of the formula wherein:
Prot is a hydroxy protecting group selected from the group consisting of hindered silyl groups, benzyl, substituted benzyl, and acyl groups of the formula wherein R5 is straight or branched chain alkyl of 1 to 6 carbons or phenyl;

X is a perfluoroalkane sulfonyloxy group, a nitro-substituted benzene sulfonyloxy group, or fluorosulfonyloxy;
Y1 is chloro, bromo, or iodo;
R1, R2, R3 and R4 are independently selected from the group consisting of straight or branched chain alkyl of 1 to 10 carbons and substituted straight or branched chain alkyl of 1 to 10 carbons;
substituted straight or branched chain alkyl of 1 to 10 carbons refers to such alkyl groups having one, two, or three substituents selected from the group consisting of alkoxy of 1 to 6 carbons and aryl; and aryl refers to phenyl and phenyl having one, two, or three substituents selected from the group consisting of alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, chloro, bromo, iodo, and fluoro.
4. The process of Claim 3 wherein:
Prot is selected from the group consisting of t-butyldimethylsilyl, t-butyldiphenylsilyl, (tri-phenylmethyl)dimethylsilyl, methyldiisopropylsilyl, triisopropylsilyl, benzyl, p-methoxybenzyl, acetyl, and benzoyl;
X is selected from the group consisting of trifluoromethanesulfonyloxy, p-nitrobenzene-sulfonyloxy, and fluorosulfonyloxy;
Y1 is chloro or iodo; and R1, R2, R3 and R4 are each n-butyl or R1, R2, and R3 are each ethyl and R4 is benzyl.
5. The process of Claim 4 wherein:
Prot is benzoyl;
X is trifluoromethanesulfonyloxy;
Y1 is iodo; and R1, R2, R3 and R4 are each n-butyl; or Prot is benzoyl;
X is trifluoromethanesulfonyloxy;
Y1 is iodo; and R1, R2 and R3 are each ethyl and R4 is benzyl;
or Prot is benzoyl;
X is trifluoromethanesulfonyloxy;
Y1 is chloro; and R1, R2, R3 and R4 are each n-butyl; or Prot is benzoyl;
x is p-nitrobenzenesulfonyloxy;
Y is iodo; and R1, R2, and R3 are each ethyl and R4 is benzyl.
6. A process for preparing the antiviral agent [1R- (1.alpha., 2.beta.,3.alpha.)]-2-amino-9-[2,3-bis(hydroxy-methyl)cyclobutyl]-1,9-dihydro-6H-purin-6-one which comprises a) reacting a purine salt of the formula with bis(2,3-protected hydroxymethyl)cyclobutane of the formula to give the cyclobutyl purine of the formula wherein:
Prot is a hydroxy protecting group selected from the group consisting of hindered silyl groups, benzyl, substituted benzyl, and acyl groups of the formula wherein R5 is straight or branched chain alkyl of 1 to 6 carbons or phenyl;
X is a perfluoroalkane sulfonyloxy group, a nitro-substituted benzene sulfonyloxy group, or fluorosulfonyloxy;
Y1 is chloro, bromo, or iodo;
R1, R2, R3 and R4 are independently selected from the group consisting of straight or branched chain alkyl of 1 to 10 carbons and substituted straight or branched chain alkyl of 1 to 10 carbons;
substituted straight or branched chain alkyl of 1 to 10 carbons refers to such alkyl groups having one, two, or three substituents selected from the group consisting of alkoxy of 1 to 6 carbons and aryl; and aryl refers to phenyl and phenyl having one, two, or three substituents selected from the group consisting of alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, chloro, bromo, iodo, and fluoro;
b) treating the product from part (a) to remove the hydroxy protecting groups and give the cyclobutyl purine of the formula c) treating the product of part (b) to convert the Y1 substituent to a 6-oxo substituent and then separating the desired antiviral product from the reaction mixture.
7. The process of Claim 6 wherein:
Prot is a hindered silyl group, step (b) comprises treating the product from part (a) with a fluoride ion, and step (c) comprises acid hydrolysis;
or Prot is benzyl or substituted benzyl, step (b) comprises treating the product from part (a) with boron trichloride, and step (c) comprises acid hydrolysis; or Prot is acetyl or benzoyl, step (b) comprises treating the product from part (a) with catalytic sodium methoxide in methanol, and step (c) comprises acid hydrolysis.
8. A process for preparing the antiviral agent [1R-(1.alpha., 2.beta.,3.alpha.)]-2-amino-9-[2,3-bis(hydroxy-methyl)cyclobutyl]-1,9-dihydro-6H-purin-6-one which comprises:
a) reacting a purine salt of the formula with the bis(2,3-protected hydroxymethyl)cyclo-butane of the formula to give the cyclobutyl purine of the formula wherein:

Prot is a hydroxy protecting group selected from the group consisting of benzyl, substituted benzyl, and acyl groups of the formula wherein R5 is straight or branched chain alkyl of 1 to 6 carbons or phenyl;
X is a perfluoroalkane sulfonyloxy group, a nitro-substituted benzene sulfonyloxy group, or fluorosulfonyloxy;
Y1 is chloro, bromo, or iodo;
R1, R2, R3 and R4 are independently selected from the group consisting of straight or branched chain alkyl of 1 to 10 carbons and substituted straight or branched chain alkyl of 1 to 10 carbons;
substituted straight or branched chain alkyl of 1 to 10 carbons refers to such alkyl groups having one, two, or three substituents selected from the group consisting of alkoxy of 1 to 6 carbons and aryl; and aryl refers to phenyl and phenyl having one, two, or three substituents selected from the group consisting of alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, chloro, bromo, iodo, and fluoro;
b) treating the product from part (a) to convert the Y1 substituent to a 6-oxo substituent;
and c) treating the product from part (b) to remove the hydroxy protecting groups and then separating the desired antiviral product from the reaction mixture.
9. The process of Claim 8 wherein:
Prot is benzoyl;
Y1 is iodo;
X is p-nitrobenzenesulfonyloxy or trifluoromethanesulfonyloxy;

R1, R2, R3 and R4 are each n-butyl or R1, R2 and R3 are ethyl and R4 is benzyl;
treating in step (b) comprises reacting the product from part (a) with hot aqueous acetic acid;
and treating in step (c) comprises reacting the product from part (b) with aqueous sodium hydroxide or sodium methoxide in methanol; or Prot is benzyl or substituted benzyl;
Y1 is chloro, bromo, or iodo;
X is p-nitrobenzenesulfonyloxy or trifluoromethanesulfonyloxy;
R1, R2, R3 and R4 are each n-butyl or R1, R2, and R3 are ethyl and R4 is benzyl;
treating in step (b) comprises reacting the product from part (a) with hot aqueous hydrochloric acid; and treating in step (c) comprises hydrogenolysis of the product from part (b).
10. A process for preparing the antiviral agent [1R-(1.alpha.,2.beta.,3.alpha.)]-2-amino-9-[2,3-bis(hydroxy-methyl)cyclobutyl]-1,9-dihydro-6H-purin-6-one which comprises:
a) reacting a purine salt of the formula with bis(2,3-protected hydroxymethyl)cyclobutane of the formula to give the cyclobutyl purine of the formula wherein:

Prot is an acyl group of the formula wherein R5 is straight or branched chain alkyl of 1 to 6 carbons or phenyl;
X is a perfluoroalkane sulfonyloxy group, a nitro-substituted benzene sulfonyloxy group, or fluorosulfonyloxy;
Y1 is chloro, bromo, or iodo;
R1, R2, R3 and R4 are independently selected from the group consisting of straight or branched chain alkyl of 1 to 10 carbons and substituted straight or branched chain alkyl of 1 to 10 carbons;
substituted straight or branched chain alkyl of 1 to 10 carbons refers to such alkyl groups having one, two, or three substituents selected from the group consisting of alkoxy of 1 to 6 carbons and aryl; and aryl refers to phenyl and phenyl having one, two, or three substituents selected from the group consisting of alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, chloro, bromo, iodo, and fluoro;
b) treating the product from part (a) to remove the hydroxy protecting groups and convert Y1 to a 6-methoxy substituent; and c) treating the product from part (b) to convert the 6-methoxy substituent to a 6-oxo and then separating the desired antiviral product from the reaction mixture.
11. The process of Claim 10 wherein:
Prot is benzoyl;
X is p-nitrobenzenesulfonyloxy or trifluoromethanesulfonyloxy;
R1, R2, R3 and R4 are each n-butyl or R1, R2, and R3 are ethyl and R4 is benzyl;
Y1 is iodo;
treating in step (b) comprises reacting the product from part (a) with excess sodium methoxide in methanol; and treating in step (c) comprises acid hydrolysis of the product from part (b) with hot aqueous hydrochloric acid.
12. A process for preparing the antiviral agent [1R-(1.alpha.,2.beta.,3.alpha.)]-2-amino-9-[2,3-bis(hydroxy-methyl)cyclobutyl]-1,9-dihydro-6H-purin-6-one which comprises:
a) reacting a purine salt of the formula with bis(2,3-protected hydroxymethyl)cyclobutane of the formula to give the cyclobutyl purine of the formula wherein:

Prot is an acyl group of the formula wherein R5 is straight or branched chain alkyl of 1 to 6 carbons or phenyl;

x is a perfluoroalkane sulfonyloxy group, a nitro-substituted benzene sulfonyloxy group, or fluorosulfonyloxy;
Y1 is chloro, bromo, or iodo;
R1, R2, R3 and R4 are independently selected from the group consisting of straight or branched chain alkyl of 1 to 10 carbons and substituted straight or branched chain alkyl of 1 to 10 carbons;
substituted straight or branched chain alkyl of 1 to 10 carbons refers to such alkyl groups having one, two, or three substituents selected from the group consisting of alkoxy of 1 to 6 carbons and aryl; and aryl refers to phenyl and phenyl having one, two, or three substituents selected from the group consisting of alkyl of 1 to 6 carbons, alkoxy of 1 to 6 carbons, chloro, bromo, iodo, and fluoro;
b) treating the product from part (a) with hot aqueous sodium or potassium hydroxide or treating the product of part (a) with an acid such as hydrochloric acid followed by sodium or potassium hydroxide and heat to remove the protecting groups and convert the Y1 substituent to a 6-oxo; and c) separating the desired antiviral product from the reaction mixture.
13. A process for preparing the compound of the formula which comprises reacting a purine salt of the formula with the compound of the formula wherein Y1 is chloro, bromo, or iodo, R1, R2, R3 and R4 are independently selected from the group consisting of straight or branched chain alkyl of 1 to 10 carbons and substituted straight or branched chain alkyl of 1 to 10 carbons;
X is a leaving group selected from the group consisting of chloro, bromo, iodo, an aryl sulfonyloxy group, an alkyl sulfonyloxy group, a substituted alkyl sulfonyloxy group, a nitro-substituted benzene sulfonyloxy group, and fluorosulfonyloxy, and Z1 is a hydroxy protected form of the carbohydrate surrogate Z.
14. The process of Claim 13 wherein Z is selected from the group consisting of , , , , , , , , , , , , and ;

Z1 represents the moiety Z wherein the hydroxy substituents are protected by members selected from the group consisting of hindered silyl groups, benzyl, substituted benzyl, acyl groups of the formula , trityl, and substituted trityl; and R5 is straight or branched chain alkyl of 1 to 6 carbons or phenyl.
CA002098033A 1992-07-13 1993-06-09 Process for preparing cyclobutane purines Abandoned CA2098033A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US91238492A 1992-07-13 1992-07-13
US912,384 1992-07-13
US08/007,950 US5874578A (en) 1992-07-13 1993-01-25 Process for preparing guanine-containing antiviral agents and purinyl salts useful in such process
US7,950 1993-01-25

Publications (1)

Publication Number Publication Date
CA2098033A1 true CA2098033A1 (en) 1994-01-14

Family

ID=26677557

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002098033A Abandoned CA2098033A1 (en) 1992-07-13 1993-06-09 Process for preparing cyclobutane purines

Country Status (12)

Country Link
US (2) US5874578A (en)
EP (1) EP0579421A2 (en)
JP (1) JPH06206879A (en)
KR (1) KR940005624A (en)
CN (1) CN1036712C (en)
CA (1) CA2098033A1 (en)
FI (1) FI933187A (en)
HU (1) HU214341B (en)
IL (1) IL106062A (en)
MX (1) MX9304140A (en)
SG (1) SG55010A1 (en)
TW (1) TW254942B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06263756A (en) * 1993-03-04 1994-09-20 Asahi Breweries Ltd Isonucleoside derivative
JPH06263793A (en) * 1993-03-04 1994-09-20 Asahi Breweries Ltd Pyranose type nucleoside derivative
IL117574A0 (en) * 1995-04-03 1996-07-23 Bristol Myers Squibb Co Processes for the preparation of cyclobutanone derivatives
US5869493A (en) * 1996-02-16 1999-02-09 Medivir Ab Acyclic nucleoside derivatives
US6703394B2 (en) 1996-02-16 2004-03-09 Medivir Ab Acyclic nucleoside derivatives
WO1998005663A1 (en) * 1996-08-01 1998-02-12 Sumika Fine Chemicals Co., Ltd. Process for producing 2-amino-6-iodopurine
US6184376B1 (en) * 1997-02-10 2001-02-06 Mediver Ab Synthesis of acyclic nucleoside derivatives
JPH1129572A (en) * 1997-07-10 1999-02-02 Ajinomoto Co Inc Purification of nucleic acid derivative
JP2000007675A (en) * 1998-06-23 2000-01-11 Sumika Fine Chemicals Co Ltd Production of quaternary alkyl ammonium salt of 6- halogenopurine derivative

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL64501A (en) * 1980-12-22 1985-07-31 Astra Laekemedel Ab 9-substituted 4-hydroxybutyl guanine derivatives,their preparation and antiviral use
US4658044A (en) * 1983-09-16 1987-04-14 Glaxo Group Limited Intermediates for uracil derivatives
IN166499B (en) * 1987-02-12 1990-05-19 Takeda Chemical Industries Ltd
US5126345A (en) * 1988-03-30 1992-06-30 E. R. Squibb & Sons, Inc. Bis (hydroxymethyl) cyclobutyl triazolopyrimidines
US5369098A (en) * 1988-07-18 1994-11-29 E. R. Squibb & Sons, Inc. Hydroxymethyl cyclobutyl purines
GB8817607D0 (en) * 1988-07-23 1988-09-01 Beecham Group Plc Novel process
AU622926B2 (en) * 1988-09-09 1992-04-30 Nippon Kayaku Kabushiki Kaisha Pyrimidine or purine cyclobutane derivatives
EP0366385B1 (en) * 1988-10-24 1993-06-09 The Wellcome Foundation Limited Guanine derivatives having antiviral activity and their pharmaceutically acceptable salts
US5153352A (en) * 1988-10-25 1992-10-06 Bristol-Myers Squibb Company Process for preparation of intermediates of carbocyclic nucleoside analogs
US5059690A (en) * 1990-03-01 1991-10-22 E. R. Squibb & Sons, Inc. Purinyl tetrahydrofurans
US5064961A (en) * 1989-12-18 1991-11-12 E. R. Squibb & Sons, Inc. Process for preparing an optically active cyclobutane nucleoside
AU635642B2 (en) * 1990-05-24 1993-03-25 E.R. Squibb & Sons, Inc. Fluorinated bis(hydroxymethyl) cyclobutyl purines and pyrimidines
US5314893A (en) * 1993-01-25 1994-05-24 Bristol-Myers Squibb Co. Antiviral tetrahydropyrans

Also Published As

Publication number Publication date
HU214341B (en) 1998-03-02
HUT64763A (en) 1994-02-28
EP0579421A3 (en) 1994-04-20
IL106062A (en) 1998-02-22
US5874578A (en) 1999-02-23
HU9302002D0 (en) 1993-10-28
SG55010A1 (en) 1998-12-21
KR940005624A (en) 1994-03-22
FI933187A0 (en) 1993-07-13
TW254942B (en) 1995-08-21
CN1036712C (en) 1997-12-17
IL106062A0 (en) 1993-10-20
US5608064A (en) 1997-03-04
MX9304140A (en) 1994-01-31
FI933187A (en) 1994-01-14
EP0579421A2 (en) 1994-01-19
CN1083813A (en) 1994-03-16
JPH06206879A (en) 1994-07-26

Similar Documents

Publication Publication Date Title
US6927291B2 (en) Method for the synthesis of 2′,3′-dideoxy-2′,3′-didehydronucleosides
JP4476802B2 (en) Production of locked nucleic acid derivatives
EP0159264B1 (en) Antiviral compounds
RU2055076C1 (en) Bis-(hydroxymethyl)-cyclobutyl-purines or pyrimidines and their pharmaceutically acceptable salts
JPH05178857A (en) Preparation of optically active cyclobutane nucleoside
SG171963A1 (en) Novel intermediate and process for preparing entecavir using same
EP0369583B1 (en) Chemical process for the preparation of purine derivatives
EP0608809B1 (en) Antiviral tetrahydropyrans
CA2098033A1 (en) Process for preparing cyclobutane purines
KR100218610B1 (en) Preparation of n-9 substituted guanine compounds
JP7025064B2 (en) Stereoselective synthesis of 4&#39;-substituted nucleoside derivatives
US5631259A (en) Cycloalkltriols containing cyclic substituents, processes and intermediate products for their preparation and their use as antiviral and antiparasitic agents
JP3146423B2 (en) Replacement pudding
JP2780843B2 (en) Purinyl and pyrimidinyl tetrahydrofurans
EP0270885A1 (en) Synthesis of purin-9-ylalkylenoxymethyl phosphonic acids
JP3156235B2 (en) Method for producing purine derivative
US5703224A (en) Antiviral c-nucleoside derivatives
RU1055123C (en) Method of producing 9-beta-d-xylofuranozyladenyna
JP2004107329A (en) Method for producing 4&#39;-c-ethynyl-2&#39;-deoxypurine nucleoside
WO1993006112A1 (en) Therapeutic nucleosides
JPS60109595A (en) Imidazole nucleoside derivative and its production
PL199375B1 (en) Method for obtaining new acyclic nucleoside aza analogues
JPH0153678B2 (en)

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20000609